| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-187 | |
| Phytochemical name or plant extracts | Docosatrienoic acid (DTA) | |
| PMID | 32781843 | |
| Literature evidence | Future In Vivo and In Vivo studies are warranted to identify the mechanism of action (MOA) for the antitumor, antioxidant and anti-inflammatory functions of DDA and DTA and explore potential applications of these two VLCPUFAs as novel nutraceutical supplements in preventing inflammatory conditions, aging and even cancer. | |
| IUPAC name | (13Z,16Z,19Z)-docosa-13,16,19-trienoic acid | |
| Phytochemicals’ class or type of plant extracts | Very long chain polyunsaturated fatty acid | |
| Source of phytochemicals or plant Extracts | Brassica carinata | |
| Geographical availability | Eritrea, Ethiopia | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | IL-1β, IL-6, IFN-γ, MCP-1, TNF-α | |
| Gene or Protein evidence | Furthermore, DDA and DTA showed strong anti-inflammatory effects in human macrophages differentiated from monocyte THP-1 cells through lowering the protein expression levels of pro-inflammatory cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6), interferon γ (IFN-γ), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor α (TNF-α). | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | Especially, DTA elicited much stronger antioxidant and pro-apoptotic effects than DHA. | |
| Cell line/ mice model | SKBR-3 and MDA-MB-231 | |
| Additional information | Future In Vivo and In Vivo studies are warranted to identify the mechanism of action (MOA) for the antitumor, antioxidant and anti-inflammatory functions of DDA and DTA and explore potential applications of these two VLCPUFAs as novel nutraceutical supplements in preventing inflammatory conditions, aging and even cancer. | |
| PubChem ID | 5312557 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:279278-1 | |
| Safety | NA |